Galena Biopharma Director Rudolph Nisi Sells 250,000 Shares (GALE)
Galena Biopharma (NASDAQ:GALE) Director Rudolph Nisi sold 250,000 shares of the company’s stock on the open market in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $5.28, for a total value of $1,320,000.00. Following the completion of the transaction, the director now directly owns 3,500 shares of the company’s stock, valued at approximately $18,480. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Galena Biopharma (NASDAQ:GALE) traded down 2.59% on Friday, hitting $5.27. 4,869,047 shares of the company’s stock traded hands. Galena Biopharma has a 1-year low of $1.65 and a 1-year high of $7.77. The stock has a 50-day moving average of $5.33 and a 200-day moving average of $3.13. The company’s market cap is $554.6 million.
A number of research firms have recently commented on GALE. Analysts at Maxim Group raised their price target on shares of Galena Biopharma from $9.00 to $11.00 in a research note to investors on Tuesday, January 21st. They now have a “buy” rating on the stock. Separately, analysts at Needham & Company raised their price target on shares of Galena Biopharma to $9.00 in a research note to investors on Tuesday, January 21st. Finally, analysts at Roth Capital raised their price target on shares of Galena Biopharma from $11.00 to $12.00 in a research note to investors on Tuesday, January 14th. Five investment analysts have rated the stock with a buy rating, Galena Biopharma currently has a consensus rating of “Buy” and an average target price of $7.36.
Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using RNAi-targeted and immunotherapy technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.